DRD5 and schizophrenia: On the other hand, the antagonists targeting GABRG-3, GABRG-4, DRD5, ADR -A1D/–B2, CHRM-3, and SLC6A4 (all elevated by FD) are under investigation for treating bipolar disorder and schizophrenia.